Browsing Tag
Victor Perlroth
4 posts
Kodiak Sciences (NASDAQ: KOD) bets Phase 3 momentum and 2027 cash runway can turn pipeline promise into a retina franchise
Kodiak Sciences is chasing a retina comeback with Phase 3 Zenkuda data, a longer cash runway, and major catalysts ahead. Read what happens next.
Kodiak Sciences’ KSI-301 fails to meet primary endpoint in wet AMD trial
Kodiak Sciences said that its antibody biopolymer conjugate KSI-301 failed to meet the primary endpoint in a phase…
KSI-301 phase 1b trial : Kodiak Sciences reports new safety, efficacy, and durability data
KSI-301 phase 1b trial : Kodiak Sciences said that its ongoing phase 1b clinical trial of its intravitreal…
DAZZLE clinical trial : Kodiak Sciences doses first patients with KSI-301 in phase 3 wet AMD trial
Kodiak Sciences said that it has treated the first patients in the phase 2 DAZZLE clinical trial of…